Prevalence of osteoporosis in the Iranian population: a systematic review and meta-analysis

Journal of Diabetes & Metabolic Disorders - Trang 1-9 - 2023
Noushin Fahimfar1,2, Elahe Hesari1, Mohammad Javad Mansourzadeh1, Kazem Khalagi1,3, Mahnaz Sanjari1, Sepideh Hajivalizadeh1, Kiarash Tanha4, Hamed Moheimani5, Fatemeh Hajivalizadeh6, Amin Doosti Irani7, Shahrzad Nematollahi8, Bagher Larijani9, Afshin Ostovar1,2,10
1Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
2Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
4Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK
5Department of Surgery, University of Pittsburgh, Pittsburgh, USA
6Center for Non-Communicable Disease Control & Prevention, Deputy of Public Health, Ministry of Health and Medical Education, Tehran, Iran
7Departments of Epidemiology and Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
8School of Physical and Occupational Therapy, McGill University, Montreal, Canada
9Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
10Endocrinology and Metabolism Research Institute, Tehran, Iran

Tóm tắt

The prevalence of osteoporosis increases as the population ages. The aim of this study was to conduct a systematic review and meta-analysis to estimate the prevalence of osteoporosis among the general population ≥ 50 years old in Iran. Multiple databases including Scopus, WOS, Medline, Embase, and Persian databases (SID and Magiran) were systematically searched to identify relevant research papers. All population-based studies estimating the prevalence of osteoporosis in the Iranian population were included and imported into Endnote software. Two authors independently reviewed the articles. The Newcastle-Ottawa Scale was used to assess the risk of bias. Statistical analysis was performed using Stata software, and a significance level of 0.05 was applied to the analyses. Totally 2117 documents were retrieved from the databases up until October 11, 2022. After reading the full texts, 10 documents were included in the study. Our results indicated that the pooled prevalence of osteoporosis in the femoral neck region was 0.19 (95%CI: 0.12–0.26) and 0.19 (95%CI: 0.13–0.25) for women and men, respectively. Pooled prevalence of spinal osteoporosis was 0.29 (95%CI: 0.21–0.38) among women and 0.16 (95%CI: 0.12–0.19) among men. The total pooled prevalence of osteoporosis was 0.38 (95%CI: 0.29–0.48) for women and 0.25 (95%CI: 0.22–0.29) for men. Our study highlights the elevated prevalence of osteoporosis among individuals aged 50 years and older, with females exhibiting higher rates. Notably, osteoporosis in the femoral neck region demonstrated the lowest prevalence in both sexes. The implementation of comprehensive strategies is imperative to address osteoporosis problems effectively.

Tài liệu tham khảo

Vandenbroucke A, Luyten FP, Flamaing J, Gielen E. Pharmacological treatment of osteoporosis in the oldest old. Clin Interv Aging. 2017;12:1065–77. Trajanoska K, Rivadeneira F. The genetic architecture of osteoporosis and fracture risk. Bone. 2019;126:2–10. Farrah Z, Jawad AS. Optimising the management of osteoporosis. Clin Med (London, England). 2020;20(5):e196–201. Fuggle NR, Curtis EM, Ward KA, Harvey NC, Dennison EM, Cooper C. Fracture prediction, imaging and screening in osteoporosis. Nat Rev Endocrinol. 2019;15(9):535–47. Parizad N, Baghi V, Karimi EB, Ghanei GR. The prevalence of osteoporosis among Iranian postmenopausal women with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(4):2607–12. Epidemiology of Osteoporosis and Fragility Fractures. 2022. Available from: https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures. Accessed 12 Sept 2021. Zamani M, Zamani V, Heidari B, Parsian H, Esmaeilnejad-Ganji SM. Prevalence of osteoporosis with the World Health Organization diagnostic criteria in the eastern Mediterranean region: a systematic review and meta-analysis. Arch Osteoporos. 2018;13(1):1–10. Larijani B, Moayyeri A, Keshtkar AA, Hossein-Nezhad A, Soltani A, Bahrami A, et al. Peak bone mass of Iranian population: the Iranian multicenter osteoporosis study. J Clin Densitom. 2006;9(3):367–74. Fahimfar N, Gharibzadeh S, Khashayar P, Rajabian R, Ranjbar Omrani G, Bahrami A, et al. Iranian multicenter osteoporosis studies (IMOS) during last decade: rationale, main findings, lessons learned and the way forward. J Diabetes Metab Disord. 2020:1–6. Fahimfar N, Noorali S, Yousefi S, Gharibzadeh S, Shafiee G, Panahi N, et al. Prevalence of osteoporosis among the elderly population of Iran. Arch Osteoporos. 2021;16(1):1–10. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2000;2(1):1–12. Jamshidian Tehrani M, Kalantari N, Azadbakht L, Rajaie A, Hooshiar-rad A, Golestan B, et al. The prevalence of osteoporosis among women aged 40-60 in Tehran. Iran J Endocrinol Metab. 2003;5(4):271–6. Hadavi M, Larijani B, Qorbani M, Eshrati B. Osteoporosis prevalence and t-score discordance between femur and lumbar spine in Iran and some related factors: imos study. Iran J Diabetes Metab. 2015;14(5):305–14. Salehi I, Khazaeli S, Najafizadeh SR, Ashraf H, Malekpour M. High prevalence of low bone density in young Iranian healthy individuals. Clin Rheumatol. 2009;28(2):173–7. Hosseinpanah F, Rambod M, Hossein-nezhad A, Larijani B, Azizi F. Association between vitamin D and bone mineral density in Iranian postmenopausal women. J Bone Miner Metab. 2008;26(1):86–92. Adine Pour A, Tohidi M, Dabbaghmanesh M, Jafari P, Fattahi M, Ranjbar Omrani G. Prevalence of osteoporosis in rural men of fars based on both local and WHO reference data. Iran J Endocrinol Metabol. 2010;12(4):393–400. Touhidi M, Adinehpour A, Dabaghmanesh M, JAFARI P, Fatahi M, Ranjbar OGH. Evaluation of bone mineral density in rural women of Kawar-Fars (Kawar cohort study). Iranian South Medical Journal. 2011;13(4):253–62. Shahriarpour Z, Nasrabadi B, Shariati-Bafghi SE, Karamati M, Rashidkhani B. Adherence to the dietary approaches to stop hypertension (DASH) dietary pattern and osteoporosis risk in postmenopausal Iranian women. Osteoporos Int. 2020;31(11):2179–88. Hemmati E, Mirghafourvand M, Mobasseri M, Shakouri SK, Mikaeli P, Farshbaf-Khalili A. Prevalence of primary osteoporosis and low bone mass in postmenopausal women and related risk factors. J Educ Health Promot. 2021;10:204. Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K. Osteoporosis: an age-related and gender-specific disease–a mini-review. Gerontology. 2009;55(1):3–12. Wanner HW, Riggs BL. Methods and application of bone densitometry in clinical diagnosis. CRC Crit Rev Clin Lab Sci. 1986;24(3):217–33. Nelson DA, Brown EB, Flynn MJ, Cody DD, Shaffer S. Comparison of dual photon and dual energy X-ray bone densitometers in a clinic setting. Skelet Radiol. 1991;20(8):591–5. Xiao P-L, Cui A, Hsu C-J, Jiang N, Xu X, Peng R, et al. Global, regional prevalence, and risk factors of osteoporosis in population-based studies: an analysis based with the World Health Organization diagnostic criteria. Preprint in The Lancet. 2022. Available at https://doi.org/10.2139/ssrn.4034473. Larijani B, Resch H, Bonjour JP, Aghai Meybodi HR, Mohajery Tehrani MR. Osteoporosis in Iran, Overview and Management. Iran J Public Health. 2007;1(36):1–13. Bagheri P, Haghdoost AA, Dortaj RE, Halimi L, Vafaei Z, Farhangnia M, et al. Ultra analysis of prevalence of osteoporosis in iranian women. A Systematic Review and Meta-analysis. Iranian Journal of Endocrinology and Metabolism. 2011;13(3):315–25. Irani AD, Poorolajal J, Khalilian A, Esmailnasab N, Cheraghi Z. Prevalence of osteoporosis in Iran: a meta-analysis. J Res Med Sci. 2013;18(9):759. Hemmati F, Sarokhani D, Sayehmiri K, Motadayen M. Prevalence of osteoporosis in postmenopausal women in Iran: a systematic review and meta-analysis. Iran J Obstet Gynecol Infertil. 2018;21(3):90–102. Azadvari M, Mirmosayyeb O, Hosseini M, Vaheb S, Razavi SZE. The prevalence of osteoporosis/osteopenia in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Neurol Sci. 2022;43(6):3879–92. Moshayedi S, Tasorian B, Almasi-Hashiani A. The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis. Sci Rep. 2022;12(1):15844. Nourmohammadi H, Abdan Z, Hashemipour SMA, Sarokhani D, Abdan M, Fakhri M, et al. Prevalence of osteoporosis and osteopenia in people over 60 years in Iran: a systematic review and meta-analysis. Int J Prev Med. 2022;13(1):11. Eghbali T, Abdi K, Nazari M, Mohammadnejad E, Gheshlagh RG. Prevalence of osteoporosis among Iranian postmenopausal women: a systematic review and Meta-analysis. Clin Med Insights Arthritis Musculoskelet Disord. 2022;15:11795441211072471.
Thông tin
Thông tin xuất bản

Journal of Diabetes & Metabolic Disorders

1-9

Thông tin tác giả